Company intelligence / Profile preview

APEX PWR

Vancouver, British Columbia, Canada

Ownership: Private
Development stage: Other

Overview

Apex Labs is a clinical-stage pharmaceutical company focused on developing evidence-based psychedelic therapies for mental health conditions, with a primary focus on veterans. The company's lead program, APEX-52, is a microdose psilocybin formulation designed for take-home use to treat post-traumatic stress disorder (PTSD). Apex Labs aims to bridge the gap between traditional pharmaceutical standards and psychedelic medicine through rigorous clinical trials and standardized dosing. Their business model emphasizes accessibility and safety, targeting large-scale mental health indications including depression and anxiety.

Therapeutic areas: PsychiatryNeurology
Modalities: Small moleculeBiologicPeptides
Industry: Biotech

Beyond the preview

Go deeper on APEX PWR.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APEX PWR.

Explore the full profile